Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

US11344552B2 · kind B2 · utility

Assignee

• IPSEN BIOPHARM LIMITED · GB

Inventors

• Eliel Bayever · New York, US
• Sarah F. Blanchette · Lynnfield, US
• Jonathan Basil Fitzgerald · Arlington, US
• Daniel F. Gaddy · Cambridge, US
• Bart S. Hendriks · Belmont, US
• Ashish Kalra · Belmont, US
• Helen Lee · Élancourt, FR

Key dates

• Filing date: Nov 10, 2017
• Grant date: May 31, 2022
• Expiry date: Nov 10, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.